Amarantus BioScience Holdings, Inc. announced the appointment of Barney Monte as interim Chief Operating Officer and Chief Financial Officer. Mr. Monte brings over 20 years of capital markets experience to Amarantus, including 15+ year in investment banking and is being brought into Amarantus to assist in completing the Company's restructuring plan and concurrent capital raise via regulations created under JOBS Act. Concurrently, the Company promoted Brian E. Harvey, MD, PhD to the role of Chief Regulatory Advisor, assisting the Company's subsidiaries in updating their regulatory strategy in preparation for launching the next phase of their respective clinical development programs. Dr. Harvey brings over 30 years of biopharmaceutical experience to Amarantus, including over 11 years at the US Food & Drug Administration (FDA). Mr. Monte has over 20 years of experience in the financial services industry where he has held senior level positions within investment banking and private equity. Mr. Monte co-founded Ozado Partners LLC. Prior to co-founding Ozado Partners, Mr. Monte's senior-level investment banking positions included head of International and Asia investment banking for a middle market focused U.S. based broker-dealer. Over his tenure, Mr. Monte has acted as a principal and agent in assisting companies raise private capital, IPOs, secondary offerings, debt offerings and M&A advisory services where he has invested, raised or advised on over $10.0 billion worth of transactions.
Dr. Harvey recently served as Vice President of U.S Regulatory Strategy at Pfizer, where he led U.S.FDA regulatory interactions across all Pfizer business units and was a member of the CEO's Senior Leadership Council (SLC). He led the Pfizer efforts on the PhRMA Regulatory Affairs Coordinating Committee (RACC). In addition, he was responsible for supervisory oversight of U.S. Regulatory Policy & Intelligence functions and the U.S. Advertising & Promotion activities. He played an early role in PDUFA VI Preparation, the PhRMA Steering Committee and the 21st Century Cures initiatives. Prior to his time at Pfizer, Dr. Harvey served as Vice President of Regulatory Policy at Sanofi, where he was the head Liaison with U.S. Food and Drug Administration (FDA), served on the International Biologics and Biotechnology Taskforce and Biologics Key Issues Team, was on the Biotechnology Industry Organization (BIO) Regulatory Affairs Committee (RAC). Prior to Sanofi, Dr. Harvey spent 11 years with FDA in increasing positions of responsibility across the organization including Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) and the Center for Devices and Radiological Health (CDRH). From 2000 to 2001, Dr. Harvey served as an American Political Science Association (APSA) Congressional Fellow on behalf of FDA. Dr. Harvey received his PhD, then MD from the University of Connecticut.